Recruiting studies: Myeloproliferative Overlap Neoplasms

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Ruxolitinib Before, During and After Hematopoietic Cell Transplant in Older Patients With Myelofibrosis and Myelodysplas
Phase 2 · 1 location(s) · Fred Hutchinson Cancer Center · NCT07228624 Momelotinib in Combination With Hypomethylating Agent for Chronic Phase Myelodysplastic Syndromes/Myeloproliferative Ove
EARLY_Phase 1 · 1 location(s) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · NCT07071155 Screening Study for KIT D816V Mutated Mast Cell Disease in Select Populations
Phase N/A · 19 location(s) · Blueprint Medicines Corporation · NCT07143669 Onvansertib for the Treatment of Recurrent or Refractory Chronic Myelomonocytic Leukemia and Myelodysplastic Syndrome/MP
Phase 1 · 1 location(s) · Mayo Clinic · NCT05549661 Axatilimab With or Without Azacitidine for the Treatment of Patients With Advanced Phase Myeloproliferative Neoplasms, M
Phase 1/Phase 2 · 1 location(s) · Uma Borate · NCT06523556 Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell Transplantation
Phase 1 · 2 location(s) · Dana-Farber Cancer Institute · NCT06138587

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.